DuctoCount: Automated Bile-Duct Quantification for Suspected Drug-Induced VBDS
Software for doctors that automatically counts bile ducts in liver slides to diagnose a rare disease.
An image-analysis add-on for digital pathology that automatically counts bile ducts in liver biopsy slides and reports an objective 'ductopenia' score, standardizing diagnosis of drug-induced vanishing bile duct syndrome — a rare condition in which medications destroy the liver's small bile ducts.
Concept
Drug-induced vanishing bile duct syndrome (VBDS) is a rare, severe form of liver injury in which a medication triggers progressive loss of the small intrahepatic bile ducts. The diagnosis ultimately rests on a pathologist visually judging whether bile ducts are missing from the biopsy's portal tracts — a subjective, expert-dependent read of the very lesion that defines the disease.
DuctoCount is an image-analysis module that plugs into standard whole-slide digital pathology platforms. On a liver biopsy (H&E plus routine duct stains such as CK7/CK19), it:
- Segments portal tracts;
- Identifies bile duct profiles within each tract;
- Computes the bile-duct-to-portal-tract ratio and maps it to a standardized ductopenia grade;
- Returns a one-page structured report flagging values consistent with drug-induced ductopenia, alongside the drug-exposure context supplied by the treating team.
The single wedge: convert the defining but subjective histologic finding of VBDS into a reproducible number. Buyers are hospital pathology departments, reference labs offering hepatopathology second opinions, and pharmaceutical safety teams reading drug-induced liver injury (DILI) case biopsies. It is a read-and-report diagnostic, not a therapy.
Why now
- A dedicated review in Seminars in Liver Disease consolidates drug-induced VBDS 'from pathogenesis to diagnosis and therapeutics' [0], confirming the syndrome is codified as a distinct drug-induced cholestatic entity whose diagnosis hinges on demonstrating bile-duct loss — a defined target lesion that image analysis can quantify.
- The rare-disease diagnostic odyssey report [6] documents that rare conditions are diagnosed late and inconsistently without structured tools and coding; VBDS is a textbook rare-disease workup, and the expert biopsy read is its scarcest, most variable step.
- Cholestatic liver diseases are hard to tell apart: the association between inflammatory bowel disease and hepatobiliary dysfunction such as primary sclerosing cholangitis only became firmly established once better diagnostic tools arrived [3]. An objective duct count gives pathologists a measurable anchor for separating drug-induced ductopenia from other cholestatic entities.
Written by GLM · 8 Oct 2026
AI assessment
A highly focused diagnostic tool that converts a subjective, expert-dependent pathology read into a quantitative score for a specific rare disease, mirroring the successful logic of the AirwayNorm model.
- Evidence strength 4/5
- The idea is grounded in a specific clinical review confirming that VBDS diagnosis hinges on the histological demonstration of bile-duct loss, a clear target for image analysis.
- Market pull 3/5
- While the condition is rare, the high stakes of drug-induced liver injury (DILI) create strong urgency for pharmaceutical safety teams and reference labs.
- Novelty & moat 4/5
- It applies a quantitative normative scoring approach to a human clinical pathology gap, distinguishing it from the rat-based AirwayNorm and the non-imaging liver tools in the catalog.
- Feasibility 4/5
- The use of CK7/CK19 stains provides high-contrast markers that make segmentation and counting technically straightforward for a small AI team.
- Wedge clarity 5/5
- The wedge is exceptionally sharp: a single-purpose module to quantify ductopenia in suspected VBDS cases.
- Simplicity / focus 5/5
- The product is a single, focused image-analysis add-on with one clear output, avoiding any 'platform' bloat.
Scored by Gemma 4 · 8 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.
Persona discussion
AI personas trained on real people's expertise debate this idea as it evolves.
View the discussion →Act on this idea
Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.
Who benefits
- Indica Labscompany
Its HALO image-analysis platform is already installed in pathology labs worldwide; a validated bile-duct quantification module is a direct product-line extension into hepatology, an indication with little dedicated tooling.
- Drug-Induced Liver Injury Network (DILIN)organization
This NIH-funded network adjudicates DILI causality across sites; a reproducible duct quantification would standardize the histology component of its adjudication for cholestatic cases.
- PathAIcompany
Builds AI pathology algorithms and partners with pharma on trial endpoints; a standardized ductopenia read opens a rare-DILI niche and a companion offering for cholestatic drug-safety programs.
- Mayo Clinic Laboratoriesorganization
A high-volume reference lab selling expert liver-pathology second opinions; automation standardizes rare-case reads and shortens turnaround while scarce hepatopathologists focus on interpretation.
Research it builds on
- Seminars in Liver DiseaseAnwar, Abid A.; Jalan-Sakrikar, Nidhi; Huebert, Robert C.: · 2026 · 211 citationsAll ideas from this paper →
- Interactions Between Chronic Liver Disease and Inflammatory Bowel DiseaseEdward V. Loftus, William J. Sandborn, Keith D. Lindor et al. · 1997 · 61 citationsAll ideas from this paper →
- The Diagnostic Odyssey in rare diseases; a Task and Finish Group report for the Department of Health and Social CareTrevor Cole · 2022 · 7 citationsAll ideas from this paper →